Device Trial Radar · NCT04539964
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
243
Actual
Start
Jan 11, 2021
Primary completion
May 16, 2024
Study completion Oct 2027
Sponsor
- Lead sponsor
- SetPoint Medical CorporationNot on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The study device contains a miniaturized stimulator (implant) that is surgically placed under general anesthesia on the vagus nerve through a small incision on the left side of the neck (implant procedure). The study will enroll up to 250 subjects at up to 45 sites. All eligible subjects will undergo the implant procedure. Half of the subjects will receive active stimulation (treatment) and the other half will receive non-active stimulation (control). After completing primary endpoint assessments at Week 12, there will be a one-way crossover of control subjects to active stimulation and a 252-week open-label follow-up with all subjects (treatment and control) receiving active stimulation to evaluate long-term safety.
Conditions
- Rheumatoid Arthritis
Interventions
Implant ProcedureProcedure
The SetPoint System (study device) contains a miniaturized stimulator (implant) that is surgically implanted inside the left side of the neck on the vagus nerve (implant procedure). All eligible subjects will undergo the surgery under general anesthesia in outpatient settings.
Conventional Synthetic DMARDDrug
All subjects will continue to take at least one type of conventional synthetic DMARD at the same stable dose as for 4 weeks prior to consent
Active stimulationDevice
Active stimulation for 1 min once per day
Non-active stimulationDevice
Non-active stimulation for 1 min once per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- the American College of Rheumatology (ACR) 20 ResponseTime frame: Week 12
Locations
43 sites in 1 country. Site status is shown where the registry gives one.
Arizona Arthritis ans Rheumatology Research, PPLC
Mesa, Arizona
Arizona Arthritis Rheumatology & Research, PLLC
Phoenix, Arizona
Arizona Arthritis & Rheumatology Research, PLLC
Tucson, Arizona
40 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.